{"id":"NCT00175916","sponsor":"UCB Pharma","briefTitle":"Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy","officialTitle":"An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2019-05","completion":"2019-05","firstPosted":"2005-09-15","resultsPosted":"2020-07-16","lastUpdate":"2021-08-17"},"enrollment":853,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Brivaracetam (ucb 34714)","otherNames":[]}],"arms":[{"label":"Brivaracetam","type":"EXPERIMENTAL"}],"summary":"This trial, evaluating the long-term safety and tolerability of brivaracetam, will give subjects suffering from epilepsy, who may have benefited from brivaracetam, the opportunity to continue the treatment. The study will also evaluate the maintenance of efficacy over time of brivaracetam for subjects with partial onset seizures (POS)/primary generalized seizures (PGS).","primaryOutcome":{"measure":"Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE)","timeFrame":"From Entry Visit until Last Visit (up to 162 months)","effectByArm":[{"arm":"Brivaracetam (SS)","deltaMin":84.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":153,"countries":["United States","Austria","Belgium","Canada","Czechia","Finland","France","Germany","Hong Kong","Hungary","Israel","Italy","Netherlands","Norway","Poland","Russia","Serbia","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Tunisia","Ukraine"]},"refs":{"pmids":["34218211","33461041","26899665"],"seeAlso":["http://www.briviact.com/briviact-PI.pdf?v=1479491757","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":248,"n":853},"commonTop":["Headache","Nasopharyngitis","Dizziness","Convulsion","Fatigue"]}}